Free tool
FAERS Monitor: Savaysa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206316 or its brand name (Savaysa, Edoxaban Tosylate). Reports on generic versions are filed under their own applications.
Reports
6,825
Serious
6,132
90% of reports
Hospitalization
3,600
Death reported
899
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia329
- off label use323
- renal impairment295
- dyspnoea274
- cerebral infarction273
- cardiac failure270
- nausea247
- atrial fibrillation226
- pneumonia224
- diarrhoea216
- fall214
- gastrointestinal haemorrhage207
- acute kidney injury200
- dizziness199
- fatigue195
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2015 | 345 |
| 2016 | 253 |
| 2017 | 130 |
| 2018 | 77 |
| 2019 | 96 |
| 2020 | 119 |
| 2021 | 569 |
| 2022 | 1,151 |
| 2023 | 1,178 |
| 2024 | 1,188 |
| 2025 | 993 |
| 2026 | 725 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,334 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cerebral infarctionSignal | 273 | 34.8 | 31.0 | 8,842 |
| renal impairmentSignal | 295 | 10.9 | 9.7 | 2,631 |
| cardiac failureSignal | 270 | 10.4 | 9.2 | 2,285 |
| gastrointestinal haemorrhageSignal | 207 | 7.6 | 6.7 | 1,192 |
| atrial fibrillationSignal | 226 | 7.2 | 6.3 | 1,196 |
| anaemiaSignal | 329 | 5.3 | 4.8 | 1,159 |
| acute kidney injurySignal | 200 | 4.0 | 3.5 | 456 |
| pneumoniaSignal | 224 | 2.1 | 1.9 | 136 |
| fall | 214 | 2.0 | 1.7 | 105 |
| dyspnoea | 274 | 1.5 | 1.3 | 45 |
| dizziness | 199 | 1.2 | 1.1 | 9 |
| off label use | 323 | 1.1 | 1.0 | 5 |
| diarrhoea | 216 | 1.0 | 0.9 | 0 |
| nausea | 247 | 1.0 | 0.9 | 0 |
| fatigue | 195 | 0.8 | 0.7 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.